Fenofibrate suppresses the progression of hepatoma by downregulating osteopontin through inhibiting the PI3K/AKT/Twist pathway.

MLA

Chen, Weiqing, et al. “Fenofibrate Suppresses the Progression of Hepatoma by Downregulating Osteopontin through Inhibiting the PI3K/AKT/Twist Pathway.” Naunyn-Schmiedeberg’s Archives of Pharmacology, vol. 397, no. 2, Feb. 2024, pp. 1025–35. EBSCOhost, https://doi.org/10.1007/s00210-023-02604-4.

APA

Chen, W., Chen, F., Gong, M., Ye, L., Weng, D., Jin, Z., & Wang, J. (2024). Fenofibrate suppresses the progression of hepatoma by downregulating osteopontin through inhibiting the PI3K/AKT/Twist pathway. Naunyn-Schmiedeberg’s Archives of Pharmacology, 397(2), 1025–1035. https://doi.org/10.1007/s00210-023-02604-4

Chicago

Chen, Weiqing, Feihua Chen, Mouchun Gong, Lijun Ye, Dengcheng Weng, Zhaoqing Jin, and Jianjiang Wang. 2024. “Fenofibrate Suppresses the Progression of Hepatoma by Downregulating Osteopontin through Inhibiting the PI3K/AKT/Twist Pathway.” Naunyn-Schmiedeberg’s Archives of Pharmacology 397 (2): 1025–35. doi:10.1007/s00210-023-02604-4.